A Prospective Study on Effectiveness of Sitagliptin on Glycemic Control, Blood Pressure and Serum Lipid Profile Levels in Type – II Diabetes Mellitus Patients

Abstract

Type-II Diabetes mellitus (DM) is chronic metabolic disorder characterized by high levels of sugar in the blood (hyperglycemia).The aim of the study was to find out the effectiveness of sitagliptin on glycemic control,blood pressure and serum lipid profile levels in Type-II Diabetes mellitus patients. And objective of the study was to assess the effect of sitagliptin (DPP-4 inhibitor ) a oral antidiabetic drug on blood sugar levels , body weight , blood pressure(systolic and diastolic), and serum lipid profile levels (TG,TC,HDL-C,LDL-C) in Type-II Diabetes mellitus patients.Materials and Methods: This study was a prospective observational study conducted in ESI Hospital, Chennai, Tamil Nadu from September 2019 – March 2020. 70 patients were grouped into group – 1 and group – 2 , were the group – 1 receiving Metformin(500mg - twice a day ) and Glimepiride(1 or 2mg - once a day) and group – 2 receiving Metformin (500mg - twice a day), Sitagliptin(100mg - once a day), Glimepiride( 1or 2mg - once a day) for 12 weeks. Blood samples were obtained at baseline and 12 week to examine HbA1c(hemoglobin A1c) , FBS(fasting blood sugar), RBS(random blood sugar), PPBS(postprandial blood sugar), TC(total cholesterol), TG(triglycerides), LDL-C(low density lipoprotein cholesterol), HDL-C(high density lipoprotein cholesterol) and SBP(systolic blood pressure), DBP(diastolic blood pressure), body weight are recorded.Results: There was a significant reduction of glycemic level, blood pressure level, serum lipid profile level and bodyweight seen in groups – 2 with  p value  <0.05. Conclusion: Sitagliptin could have a beneficial effect not only on blood glucose levels but also shows some favourable effects on body weight, blood pressure and serum lipid profile levels cannot be denied.